Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.

Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, Horwitz S, Fields P, Tanase A, Bumbea H, Cwynarski K, Taylor G, Waldmann TA, Bittencourt A, Marcais A, Suarez F, Sibon D, Phillips A, Lunning M, Farid R, Imaizumi Y, Choi I, Ishida T, Ishitsuka K, Fukushima T, Uchimaru K, Takaori-Kondo A, Tokura Y, Utsunomiya A, Matsuoka M, Tsukasaki K, Watanabe T.

J Clin Oncol. 2019 Jan 18:JCO1800501. doi: 10.1200/JCO.18.00501. [Epub ahead of print]

PMID:
30657736
2.

NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study.

Cheminant M, Bruneau J, Malamut G, Sibon D, Guegan N, van Gils T, Cording S, Trinquand A, Verkarre V, Lhermitte L, Brousse N, Jannot AS, Khater S, Frenzel L, Delarue R, Suarez F, Marçais A, Mulder CJ, Macintyre E, Asnafi V, Pouyet L, Bonnafous C, Lhospice F, Molina TJ, Meresse B, Cellier C, Cerf-Bensussan N, Hermine O; CELAC network°.

Gut. 2018 Nov 17. pii: gutjnl-2018-317371. doi: 10.1136/gutjnl-2018-317371. [Epub ahead of print]

PMID:
30448772
3.

A point mutation in the Ncr1 signal peptide impairs the development of innate lymphoid cell subsets.

Almeida FF, Tognarelli S, Marçais A, Kueh AJ, Friede ME, Liao Y, Willis SN, Luong K, Faure F, Mercier FE, Galluso J, Firth M, Narni-Mancinelli E, Rais B, Scadden DT, Spallotta F, Weil S, Giannattasio A, Kalensee F, Zöller T, Huntington ND, Schleicher U, Chiocchetti AG, Ugolini S, Herold MJ, Shi W, Koch J, Steinle A, Vivier E, Walzer T, Belz GT, Ullrich E.

Oncoimmunology. 2018 Aug 15;7(10):e1475875. doi: 10.1080/2162402X.2018.1475875. eCollection 2018.

4.

Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma.

Lemonnier F, Dupuis J, Sujobert P, Tournillhac O, Cheminant M, Sarkozy C, Pelletier L, Marçais A, Robe C, Fataccioli V, Haioun C, Hermine O, Gaulard P, Delarue R.

Blood. 2018 Nov 22;132(21):2305-2309. doi: 10.1182/blood-2018-04-840538. Epub 2018 Oct 2. No abstract available.

PMID:
30279227
5.

Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia.

Contejean A, Resche-Rigon M, Tamburini J, Alcantara M, Jardin F, Lengliné E, Adès L, Bouscary D, Marçais A, Lebon D, Chabrot C, Terriou L, Barraco F, Banos A, Bussot L, Cahn JY, Hirsch P, Maillard N, Simon L, Fornecker LM, Socié G, de Latour RP, de Fontbrune FS.

Haematologica. 2019 Feb;104(2):256-262. doi: 10.3324/haematol.2018.198440. Epub 2018 Sep 27.

6.

One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.

Besson L, Charrier E, Karlin L, Allatif O, Marçais A, Rouzaire P, Belmont L, Attal M, Lombard C, Salles G, Walzer T, Viel S.

Front Immunol. 2018 Apr 13;9:704. doi: 10.3389/fimmu.2018.00704. eCollection 2018.

7.

An immunosuppressive pathway for tumor progression.

Marçais A, Walzer T.

Nat Med. 2018 Mar 6;24(3):260-261. doi: 10.1038/nm.4508. No abstract available.

PMID:
29509752
8.

T-bet and Eomes govern differentiation and function of mouse and human NK cells and ILC1.

Zhang J, Marotel M, Fauteux-Daniel S, Mathieu AL, Viel S, Marçais A, Walzer T.

Eur J Immunol. 2018 May;48(5):738-750. doi: 10.1002/eji.201747299. Epub 2018 Feb 28. Review.

PMID:
29424438
9.

Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: A report on behalf of the French Reference Center for Aplastic Anemia.

Peffault de Latour R, Tabrizi R, Marcais A, Leblanc T, Lamy T, Mohty M, Tavitian S, Jubert C, Pasquet M, Galambrun C, Nguyen S, Cahn JY, Braun T, Deconinck E, Bay JO, Sicre de Fontbrune F, Barraco F, Socié G.

Am J Hematol. 2018 May;93(5):635-642. doi: 10.1002/ajh.25050. Epub 2018 Feb 14.

PMID:
29377260
10.

Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-α.

Macchi B, Balestrieri E, Frezza C, Grelli S, Valletta E, Marçais A, Marino-Merlo F, Turpin J, Bangham CR, Hermine O, Mastino A, Bazarbachi A.

Blood Adv. 2017 May 5;1(12):748-752. doi: 10.1182/bloodadvances.2016001370. eCollection 2017 May 9.

11.

S1PR5 is essential for human natural killer cell migration toward sphingosine-1 phosphate.

Drouillard A, Mathieu AL, Marçais A, Belot A, Viel S, Mingueneau M, Guckian K, Walzer T.

J Allergy Clin Immunol. 2018 Jun;141(6):2265-2268.e1. doi: 10.1016/j.jaci.2017.11.022. Epub 2017 Dec 14. No abstract available.

PMID:
29248494
12.

Human Naive and Memory T Cells Display Opposite Migratory Responses to Sphingosine-1 Phosphate.

Drouillard A, Neyra A, Mathieu AL, Marçais A, Wencker M, Marvel J, Belot A, Walzer T.

J Immunol. 2018 Jan 15;200(2):551-557. doi: 10.4049/jimmunol.1701278. Epub 2017 Dec 13.

13.

Regulation of mTOR, Metabolic Fitness, and Effector Functions by Cytokines in Natural Killer Cells.

Viel S, Besson L, Marotel M, Walzer T, Marçais A.

Cancers (Basel). 2017 Sep 28;9(10). pii: E132. doi: 10.3390/cancers9100132. Review.

14.

Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Le Bourgeois A, Labopin M, Blaise D, Ceballos P, Vigouroux S, Peffault de Latour R, Marçais A, Bulabois CE, Bay JO, Chantepie S, Deconinck E, Daguindau E, Contentin N, Yakoub-Agha I, Cornillon J, Mercier M, Turlure P, Charbonnier A, Rorhlich PS, N'Guyen S, Maillard N, Marchand T, Mohty M, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Ann Oncol. 2017 Sep 1;28(9):2191-2198. doi: 10.1093/annonc/mdx274.

PMID:
28911060
15.

Adult T cell leukemia aggressivenness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression.

Marçais A, Waast L, Bruneau J, Hanssens K, Asnafi V, Gaulard P, Suarez F, Dubreuil P, Gessain A, Hermine O, Pique C.

Oncotarget. 2016 Nov 26;8(32):52256-52268. doi: 10.18632/oncotarget.13665. eCollection 2017 Aug 8.

16.

High mTOR activity is a hallmark of reactive natural killer cells and amplifies early signaling through activating receptors.

Marçais A, Marotel M, Degouve S, Koenig A, Fauteux-Daniel S, Drouillard A, Schlums H, Viel S, Besson L, Allatif O, Bléry M, Vivier E, Bryceson Y, Thaunat O, Walzer T.

Elife. 2017 Sep 6;6. pii: e26423. doi: 10.7554/eLife.26423.

17.

Monitoring molecular response in adult T-cell leukemia by high-throughput sequencing analysis of HTLV-1 clonality.

Artesi M, Marçais A, Durkin K, Rosewick N, Hahaut V, Suarez F, Trinquand A, Lhermitte L, Asnafi V, Avettand-Fenoel V, Burny A, Georges M, Hermine O, Van den Broeke A.

Leukemia. 2017 Nov;31(11):2532-2535. doi: 10.1038/leu.2017.260. Epub 2017 Aug 16. No abstract available.

18.

Cis-perturbation of cancer drivers by the HTLV-1/BLV proviruses is an early determinant of leukemogenesis.

Rosewick N, Durkin K, Artesi M, Marçais A, Hahaut V, Griebel P, Arsic N, Avettand-Fenoel V, Burny A, Charlier C, Hermine O, Georges M, Van den Broeke A.

Nat Commun. 2017 May 23;8:15264. doi: 10.1038/ncomms15264.

19.

Overview of Targeted Therapies for Adult T-Cell Leukemia/Lymphoma.

Nasr R, Marçais A, Hermine O, Bazarbachi A.

Methods Mol Biol. 2017;1582:197-216. doi: 10.1007/978-1-4939-6872-5_15. Review.

PMID:
28357672
20.

Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy.

Gauthier J, Castagna L, Garnier F, Guillaume T, Socié G, Maury S, Maillard N, Tabrizi R, Marchand T, Malfuson J, Gac A, Gyan E, Mercier M, Béguin Y, Delage J, Turlure P, Marçais A, Nguyen S, Dulery R, Bay J, Huynh A, Daguindau E, Cornillon J, Régny C, Michallet M, Peffault de Latour R, Yakoub-Agha I, Blaise D.

Bone Marrow Transplant. 2017 May;52(5):689-696. doi: 10.1038/bmt.2016.349. Epub 2017 Jan 9.

PMID:
28067872
21.

Whole body clonality analysis in an aggressive STLV-1 associated leukemia (ATLL) reveals an unexpected clonal complexity.

Turpin J, Alais S, Marçais A, Bruneau J, Melamed A, Gadot N, Tanaka Y, Hermine O, Melot S, Lacoste R, Bangham CR, Mahieux R.

Cancer Lett. 2017 Mar 28;389:78-85. doi: 10.1016/j.canlet.2016.12.022. Epub 2016 Dec 26.

22.

Back to the drawing board: Understanding the complexity of hepatic innate lymphoid cells.

Marotel M, Hasan U, Viel S, Marçais A, Walzer T.

Eur J Immunol. 2016 Sep;46(9):2095-8. doi: 10.1002/eji.201646584.

23.

NKp46-mediated Dicer1 inactivation results in defective NK-cell differentiation and effector functions in mice.

Degouve S, Tavares A, Viel S, Walzer T, Marçais A.

Eur J Immunol. 2016 Aug;46(8):1902-11. doi: 10.1002/eji.201546163. Epub 2016 Jun 8.

24.

MicroRNAs of the miR-290-295 Family Maintain Bivalency in Mouse Embryonic Stem Cells.

Graham B, Marcais A, Dharmalingam G, Carroll T, Kanellopoulou C, Graumann J, Nesterova TB, Bermange A, Brazauskas P, Xella B, Kriaucionis S, Higgs DR, Brockdorff N, Mann M, Fisher AG, Merkenschlager M.

Stem Cell Reports. 2016 May 10;6(5):635-642. doi: 10.1016/j.stemcr.2016.03.005. Epub 2016 Apr 14.

25.

[Memory NK cells discovered in non-human primates].

Walzer T, Marçais A.

Med Sci (Paris). 2016 Mar;32(3):246-8. doi: 10.1051/medsci/20163203007. Epub 2016 Mar 23. French. No abstract available.

26.

TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway.

Viel S, Marçais A, Guimaraes FS, Loftus R, Rabilloud J, Grau M, Degouve S, Djebali S, Sanlaville A, Charrier E, Bienvenu J, Marie JC, Caux C, Marvel J, Town L, Huntington ND, Bartholin L, Finlay D, Smyth MJ, Walzer T.

Sci Signal. 2016 Feb 16;9(415):ra19. doi: 10.1126/scisignal.aad1884.

PMID:
26884601
27.

Alteration of Natural Killer cell phenotype and function in obese individuals.

Viel S, Besson L, Charrier E, Marçais A, Disse E, Bienvenu J, Walzer T, Dumontet C.

Clin Immunol. 2017 Apr;177:12-17. doi: 10.1016/j.clim.2016.01.007. Epub 2016 Jan 18.

PMID:
26794911
28.

Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.

Sibon D, Morschhauser F, Resche-Rigon M, Ghez D, Dupuis J, Marçais A, Deau-Fischer B, Bouabdallah R, Sebban C, Salles G, Brice P.

Haematologica. 2016 Apr;101(4):474-81. doi: 10.3324/haematol.2015.136408. Epub 2015 Dec 31.

29.

(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.

Chevallier P, Eugene T, Robillard N, Isnard F, Nicolini F, Escoffre-Barbe M, Huguet F, Hunault M, Marcais A, Gaschet J, Cherel M, Guillaume T, Delaunay J, Peterlin P, Eveillard M, Thomas X, Ifrah N, Lapusan S, Bodet-Milin C, Barbet J, Faivre-Chauvet A, Ferrer L, Bene MC, Le Houerou C, Goldenberg DM, Wegener WA, Kraeber-Bodéré F.

Lancet Haematol. 2015 Mar;2(3):e108-17. doi: 10.1016/S2352-3026(15)00020-4. Epub 2015 Feb 25.

PMID:
26687796
30.

Terminal NK cell maturation is controlled by concerted actions of T-bet and Zeb2 and is essential for melanoma rejection.

van Helden MJ, Goossens S, Daussy C, Mathieu AL, Faure F, Marçais A, Vandamme N, Farla N, Mayol K, Viel S, Degouve S, Debien E, Seuntjens E, Conidi A, Chaix J, Mangeot P, de Bernard S, Buffat L, Haigh JJ, Huylebroeck D, Lambrecht BN, Berx G, Walzer T.

J Exp Med. 2015 Nov 16;212(12):2015-25. doi: 10.1084/jem.20150809. Epub 2015 Oct 26.

31.

microRNAs calibrate T cell responses by regulating mTOR.

Merkenschlager M, Marcais A.

Oncotarget. 2015 Oct 27;6(33):34059-60. doi: 10.18632/oncotarget.6107. No abstract available.

32.

microRNAs regulate cell-to-cell variability of endogenous target gene expression in developing mouse thymocytes.

Blevins R, Bruno L, Carroll T, Elliott J, Marcais A, Loh C, Hertweck A, Krek A, Rajewsky N, Chen CZ, Fisher AG, Merkenschlager M.

PLoS Genet. 2015 Feb 25;11(2):e1005020. doi: 10.1371/journal.pgen.1005020. eCollection 2015.

33.

Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantation.

Vantyghem MC, Cornillon J, Decanter C, Defrance F, Karrouz W, Leroy C, Le Mapihan K, Couturier MA, De Berranger E, Hermet E, Maillard N, Marcais A, Francois S, Tabrizi R, Yakoub-Agha I; Société Française de Thérapie Cellulaire.

Orphanet J Rare Dis. 2014 Oct 29;9:162. doi: 10.1186/s13023-014-0162-0. Review.

34.

mTOR: a gate to NK cell maturation and activation.

Marçais A, Walzer T.

Cell Cycle. 2014;13(21):3315-6. doi: 10.4161/15384101.2014.972919. No abstract available.

35.

microRNA-mediated regulation of mTOR complex components facilitates discrimination between activation and anergy in CD4 T cells.

Marcais A, Blevins R, Graumann J, Feytout A, Dharmalingam G, Carroll T, Amado IF, Bruno L, Lee K, Walzer T, Mann M, Freitas AA, Boothby M, Fisher AG, Merkenschlager M.

J Exp Med. 2014 Oct 20;211(11):2281-95. doi: 10.1084/jem.20132059. Epub 2014 Oct 13.

36.

Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study.

Maury S, Rosenzwajg M, Redjoul R, Marcais A, Xhaard A, Cherai M, Cabanne L, Churlaud G, Suarez F, Socié G, Gregoire L, Debbache K, Bernard C, Beaumont JL, Azar N, Boyer O, Roudot-Thoraval F, Cohen JL, Cordonnier C, Lemoine FM, Klatzmann D.

Leukemia. 2014 Dec;28(12):2406-10. doi: 10.1038/leu.2014.237. Epub 2014 Aug 8. No abstract available.

PMID:
25102947
37.

MixMir: microRNA motif discovery from gene expression data using mixed linear models.

Diao L, Marcais A, Norton S, Chen KC.

Nucleic Acids Res. 2014;42(17):e135. doi: 10.1093/nar/gku672. Epub 2014 Jul 31.

38.

The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells.

Marçais A, Cherfils-Vicini J, Viant C, Degouve S, Viel S, Fenis A, Rabilloud J, Mayol K, Tavares A, Bienvenu J, Gangloff YG, Gilson E, Vivier E, Walzer T.

Nat Immunol. 2014 Aug;15(8):749-757. doi: 10.1038/ni.2936. Epub 2014 Jun 29.

39.

Regulation of mouse NK cell development and function by cytokines.

Marçais A, Viel S, Grau M, Henry T, Marvel J, Walzer T.

Front Immunol. 2013 Dec 12;4:450. doi: 10.3389/fimmu.2013.00450. Review.

40.

Monitoring NK cell activity in patients with hematological malignancies.

Viel S, Charrier E, Marçais A, Rouzaire P, Bienvenu J, Karlin L, Salles G, Walzer T.

Oncoimmunology. 2013 Sep 1;2(9):e26011. Epub 2013 Sep 12. Review.

41.

HTLV-1-associated arthropathy treated with anti-TNF-alpha agent.

Frenzel L, Moura B, Marcais A, Chapdelaine H, Hermine O.

Joint Bone Spine. 2014 Jul;81(4):360-1. doi: 10.1016/j.jbspin.2013.10.006. Epub 2013 Nov 28.

PMID:
24289962
42.

[Management of endocrine dysfunctions after allogeneic hematopoietic stem cell transplantation: a report of the SFGM-TC on gonadal failure and fertility].

Cornillon J, Decanter C, Couturier MA, de Berranger E, François S, Hermet E, Maillard N, Marcais A, Tabrizi R, Vantyghem MC, Bauters F, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2013 Aug;61(4):164-7. doi: 10.1016/j.patbio.2013.07.008. Epub 2013 Sep 4. French.

PMID:
24011968
43.

[Management of endocrine dysfunctions after allogeneic hematopoietic stem cell transplantation: a report of the SFGM-TC on dyslipidemia and thyroid disorders].

Cornillon J, Vantyghem MC, Couturier MA, de Berranger E, François S, Hermet E, Maillard N, Marcais A, Tabrizi R, Decanter C, Duléry R, Bauters F, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2013 Aug;61(4):168-70. doi: 10.1016/j.patbio.2013.07.010. Epub 2013 Sep 4. French.

PMID:
24011967
44.

[Management of endocrine dysfunctions after allogeneic hematopoietic stem cell transplantation: a report of the SFGM-TC on adrenal insufficiency and osteoporosis].

Cornillon J, Vantyghem MC, Couturier MA, de Berranger E, François S, Hermete E, Maillard N, Marcais A, Tabrizi R, Decanter C, Duléry R, Bauters F, Yakoub-Agha I; SFGM-TC.

Pathol Biol (Paris). 2013 Aug;61(4):171-3. doi: 10.1016/j.patbio.2013.07.009. Epub 2013 Sep 4. French.

PMID:
24011963
45.

Therapeutic options for adult T-cell leukemia/lymphoma.

Marçais A, Suarez F, Sibon D, Frenzel L, Hermine O, Bazarbachi A.

Curr Oncol Rep. 2013 Oct;15(5):457-64. doi: 10.1007/s11912-013-0332-6. Review.

PMID:
23943384
46.

Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).

Marcais A, Porcher R, Robin M, Mohty M, Michalet M, Blaise D, Tabrizi R, Clement L, Ceballos P, Daguindau E, Bilger K, Dhedin N, Lapusan S, Bay JO, Pautas C, Garban F, Ifrah N, Guillerm G, Contentin N, Bourhis JH, Yakoub Agha I, Bernard M, Cornillon J, Milpied N.

Haematologica. 2013 Sep;98(9):1467-75. doi: 10.3324/haematol.2012.080895. Epub 2013 Mar 28.

47.

Clinical trials of adult T-cell leukaemia/lymphoma treatment.

Marçais A, Suarez F, Sibon D, Bazarbachi A, Hermine O.

Leuk Res Treatment. 2012;2012:932175. doi: 10.1155/2012/932175. Epub 2012 Feb 14.

48.

Negative regulation of NKG2D expression by IL-4 in memory CD8 T cells.

Ventre E, Brinza L, Schicklin S, Mafille J, Coupet CA, Marçais A, Djebali S, Jubin V, Walzer T, Marvel J.

J Immunol. 2012 Oct 1;189(7):3480-9. Epub 2012 Aug 31.

49.

Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival.

Rubio MT, Moreira-Teixeira L, Bachy E, Bouillié M, Milpied P, Coman T, Suarez F, Marcais A, Sibon D, Buzyn A, Caillat-Zucman S, Cavazzana-Calvo M, Varet B, Dy M, Hermine O, Leite-de-Moraes M.

Blood. 2012 Sep 6;120(10):2144-54. doi: 10.1182/blood-2012-01-404673. Epub 2012 Jun 22.

50.

[Hypophosphatemia complicated with neurological manifestations during hematopoietic reconstitution].

Dubée V, Hermine O, Marçais A.

Rev Med Interne. 2012 Jan;33(1):e1-2. doi: 10.1016/j.revmed.2011.02.002. Epub 2011 Mar 9. French.

PMID:
21392866

Supplemental Content

Loading ...
Support Center